Combining an Immune Checkpoint Antibody with an Anti-Angiogenesis Inhibitor


A small phase I study combining the immune checkpoint antibody ipilimumab with the angiogenesis inhibitor antibody bevacizumab showed promising results in advanced melanoma patients in 2011. Now, researchers are continuing to study the combination of immunotherapy and anti-angiogenic agents to understand which patients could best benefit from such a combination. Continue reading…


MERTK receptor tyrosine kinase is a therapeutic target in melanoma

“Although early cutaneous melanoma is usually curable with surgery, distant metastatic melanoma is an aggressive cancer with a median overall survival time of less than 1 year. In 2012, over 75,000 new melanoma diagnoses were expected and over 9,000 deaths were projected (1). Advances in the understanding of distinct melanoma subtypes as well as melanoma immunobiology have resulted in 2 FDA-approved therapies for metastatic melanoma in 2011: vemurafenib, an inhibitor of mutant BRAF — an oncogene present in approximately 50% of melanomas — and ipilimumab, a monoclonal antibody that targets CTLA-4 (24)…”


Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint provides a survival advantage in patients with advanced disease…”


Liver Toxicity Halts Melanoma Study

Unexpected liver toxicity derailed a phase I melanoma trial of concurrent treatment with the first two targeted agents approved for the disease, according to a brief communication from investigators.


Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Background: This phase I/II study in patients with metastatic castration-resistant prostate cancer (mCRPC) explored ipilimumab as monotherapy and in combination with radiotherapy, based on the preclinical evidence of synergistic antitumor activity between anti-CTLA-4 antibody and radiotherapy. Patients and methods: In dose escalation, 33 patients (≥6/cohort) received ipilimumab every 3 weeks × 4 doses at 3, 5, or 10 mg/kg or at 3 or 10 mg/kg + radiotherapy (8 Gy/lesion)…”


Immunotherapies Take Center Stage in Treatment of Metastatic Melanoma


The promise of immunotherapy is coming to fruition with therapeutic advances in melanoma. In 1998, high-dose interleukin-2 (HD IL-2) became the first U.S. Food and Drug Administration (FDA)-approved immunotherapy for metastatic melanoma. But HD IL-2 is severely toxic and benefits only a small minority of patients. In 2011, ipilimumab became the second immunotherapy approved for metastatic melanoma. Continue reading…